NEW YORK (GenomeWeb) – WaferGen Biosystems reported after the close of the market Monday an 18 percent drop in first quarter revenues, primarily due to weak sales of its SmartChip system, though it saw a sharp increase in SmartChip consumables and services.

For the three-month period ended March 31, WaferGen's revenues slipped to $1.1 million from $1.4 million year over year, well off the average analysts' estimate of $2.2 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.